RE:RE:Given time investors will connect the dots...Where did you get this from, ScienceFirst? I was told by Dr. MacFarlane that the advantage of the Osmium compound is that it breaches the blood/brain barrier, making it the better choice for glioblastoma treatment
She said nothing about the molecules being specific to cancer cell types. In fact, I believe that Dr. MacFarlane treated her own melanoma with the Ruthenium-based PDC.
So, I'm curious about your source. ScienceFirst wrote: As Prof. McFarland once mentioned, each molecule are designed to address specific indications instead of trying to target all indications. That's how she's been successful in bringing TLD1433 close to bedside.
So far, TLD1433 has not proven to be efficient enough for prostate or melanoma. Other molecules, with more specific/different attributes are on their way (Osmium, etc ...). But TLD1433 has been successful against at least 6 indications so far, sometimes when mixed with transferrin (to become Rutherrin).